In addition to EGFR inhibitors -first (erlotinib, gefitinib), second (afatrinib, dacomitinib) or third generation (Osimertinib) inhibitors-, other pathways like ALK or ROS-1 translocations, BRAF, K RAS, RET or NTRK/ROS1 are relevant in the NSCLC landscape (5). Here, ROS1 is linked to non-small cell lung carcinoma.